Dermata Therapeutics announces new board member

Dermata Therapeutics announced the appointment of Wendell Wierenga, PhD, to its board of directors, according to a press release.

Wierenga most recently served as executive vice president of research and development at Santarus (acquired by Salix Pharmaceuticals). Before that, he served as executive vice president of research and development at both Ambit Biosciences and Neurocrine Biosciences.

“We are very excited to have Wendell be part of our board of directors. I have worked with Wendell for many years and believe he will be an invaluable asset in helping with the development of our programs from his years of experience in biotech,” Gerry Proehl, president, chief executive officer and director of Dermata Therapeutics, said in the release.

Reference: www.dermatarx.com